The growing prevalence of diabetes, primarily due to obesity, aging populations, and sedentary lifestyles, is a key factor ...

The global injectable drug delivery devices market size was estimated at USD 519 billion in 2024 and is predicted to reach ...

In brief ... 💊 A new international clinical trial found that oral semaglutide reduces the risk of major cardiovascular ...

These oral and injectable options are ones that you can stack onto other vitamins and supplements and use in conjunction with in-office treatments to address specific issues and live a longer ...

Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention ...

A large clinical trial, co-led by researchers at the UNC School of Medicine, has shown that the popular weight-loss drug ...

Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...

Injectable semaglutide has better bioavailability, researchers say, but the many patients who want an oral drug are an unmet ...

People taking an oral formulation of the glucagon-like peptide-1 (GLP-1) agonist semaglutide were 14% less likely than those taking a placebo to experience cardiovascular death, heart attack or stroke ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

This market research report provides an in-depth analysis of the Injectable Drug Delivery Market, projecting significant ...

Novo Nordisk's Phase 3b STRIDE trial shows Ozempic improves walking distance in peripheral artery disease, while the SOUL ...